We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment. Subsequently, the patient presented with a lower eyelid mass, which on excision was demonstrated to be a chalazion. Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past.
Introduction
Docetaxel is a taxane used in the treatment of patients with breast cancer, 1 metastatic non-small-cell lung cancer, 2 advanced gastric adenocarcinoma 3 and castration-resistant prostate cancer 4 as either a single-agent therapy or in combination with other drugs. Common adverse effects include neutropenic fever, anemia, hypersensitivity reactions, anorexia, mylagias, mucositis, alopecia, skin and nail toxicity, peripheral neuropathy, lacrimation disorder and conjunctivitis. [5] [6] [7] We report a 71-year-old man with castration-resistant metastatic prostate cancer who received weekly docetaxel and developed conjunctivitis and lacrimation disorder. Subsequently, he developed a lower eyelid mass that raised the possibility of a metastasis. Excisional biopsy was performed and histological examination of the lesion demonstrated it to be a chalazion. Meibomian duct inflammation and obstruction secondary to docetaxel is the plausible cause of the development of this lesion in a patient who did not have any history of eyelid lesions in the past. To our knowledge, this is the first reported case of Meibomian duct inflammation and subsequent chalazion formation induced by docetaxel.
Case report
A 71-year-old man was diagnosed with metastatic prostate cancer in March 2005. Prostate-specific antigen (PSA) was 389 ng/ml and there were metastatic lesions in the liver and bones. Initial therapy consisted of bicalutamide, leuprolide and zoledronic acid. The PSA initially decreased to 52 ng/ml in August 2005, but subsequently increased to 513 ng/ml in October 2005 indicating disease progression. Bicalutamide withdrawal had no effect. He was started on docetaxel (intravenously 35 mg/m 2 /week, 3 weeks on, 1 week off) and prednisone 5 mg orally twice daily in December 2005. PSA in December 2005 was 1082 ng/ml. The patient experienced a good response; PSA decreased to 45 ng/ml after 3 months of treatment. He did have mild drug-related side effects including paresthesias of hand and feet. In March 2006, he presented with redness and irritation of his right eye that was thought to be conjunctivitis. Docetaxel was held and the patient was prescribed sulfonamide ocular drops with instructions to follow up in the clinic in 2 weeks.
In the interim, the patient developed a slow-growing, painless right lower eyelid mass that was associated with significant irritation and lacrimation in the affected eye. There were no other visual complaints. On examination, a red, raised, well-circumscribed nodule was noted in the lower eyelid with associated injection of the right scleral conjunctiva (Figure 1) . The left eye was entirely normal. A metastatic lesion was suspected and he was referred to an ophthalmologist. Lacrimal duct stenosis was not detected on evaluation and the patient underwent excisional biopsy of the lesion. Histological examination (Figure 2 ) revealed nodular conjuctival epithelium with extensive fresh hemorrhage and a mixed acute and chronic inflammatory infiltrate, the chronic component of which showed lymphohistiocytic cells and foam cells, a picture compatible with a chalazion.
Patient's PSA increased to 211 ng/ml while his chemotherapy was being held and it was decided to restart his docetaxel on a q 3-week schedule (intravenously 60 mg/m 2 q 3 week) and monitor closely for side effects. He has since received five cycles of this therapy with a good response; PSA at last follow up is 45 mg/ml. There have been no further eyelid masses, but he continues to have mild lacrimation for which he is undergoing conservative management.
Discussion
Meibomian glands are sebaceous glands located at the rim of the eyelids. A chalazion is a non-infectious, granulomatous inflammation of the Meibomian glands initiated by irritation and obstruction of the gland. It consists of many types of immune cells, including histiocytes, multinucleate giant cells, plasma cells, polymorphonuclear leukocytes and eosinophils. 8 We report a case of chalazion formation in a patient being treated with weekly docetaxel for castrationresistant metastatic prostate cancer; we suggest the chalazion was due to Meibomian duct inflammation induced by docetaxel. Use of sulfa eye drops has not been reported to cause chalazion formation but remains a possibility. The patient had no history of prior ocular inflammation, chalazion, other cysts or styes. Although lacrimal duct stenosis is well recognized and is caused by docetaxel secretion in the tears, 9 Meibomian gland inflammation and chalazion have not been reported. Lacrimal canalicular stenosis is more common in patients receiving weekly docetaxel, as this patient, than in those receiving every-3-weeks docetaxel. 10 In our patient, there was no recurrence on a q 3-weekly schedule.
The mechanism of canalicular stenosis is postulated to be secondary to secretion of the chemotherapeutic agent in the tear film and fibrosis of the canaliculi from direct contact with the drug. 7 This is a plausible cause for Meibomian duct inflammation and subsequent blockage as in this patient. 
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